Top Markets
Coin of the day
Destiny Pharma plc Destiny Pharma plc

Destiny Pharma plc

DEST
Rangering i aksjer #41146
Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in... Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in 1996, specializing in the identification, progression, and market introduction of pharmaceutical solutions for infectious diseases. The company's clinical pipeline includes NTCD-M3, currently in Phase III trials to prevent recurring Clostridioides difficile infections. Its XF-73 program features XF-73 Nasal, undergoing Phase II development for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I for treating bacterial skin infections resistant to antibiotics. Additionally, Destiny Pharma's preclinical efforts involve SPOR-COV, a biotherapeutic product aimed at preventing COVID-19 and other viral respiratory diseases, and XF Drugs Biofilm, targeting antibiotic-resistant biofilm and bacterial aggregate infections. The company is also investigating further applications of its XF drugs for respiratory, oral mucosa, and ocular infections. Destiny Pharma maintains strategic alliances with various organizations, including China Medical System Holdings Limited, SporeGen Limited, the University of Southampton, Aston University, the University of Sheffield, Cardiff University, and Tianjin Medical University.
Aksjekurs
$0.04082105
Sist synkronisert: 2024-08-12
Markedsverdi
$39.09K
Endring (1 dag)
-19.83%
Endring (1 år)
0.00%
Land
GB
Handel Destiny Pharma plc (DEST)

Kategori

P/E-forhold for Destiny Pharma plc (DEST)
P/E-forhold per August 2026 TTM: -0.48
Ifølge Destiny Pharma plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -0.48. Ved slutten av 2022 hadde selskapet en P/E på -5.77.
P/E-forholdshistorikk for Destiny Pharma plc fra 2013 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) -0.48 -95.71%
2023 -11.22 94.28%
2022 -5.77 -50.95%
2021 -11.77 105.60%
2020 -5.73 43.10%
2019 -4.00 -23.47%
2018 -5.23 -67.89%
2017 -16.28 -77.40%
2016 -72.04 -17.08%
2015 -86.89 68.93%
2014 -51.43 -47.63%
2013 -98.22 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
28.05 -5,933.65%
US
31.14 -6,577.58%
NL
- -
CH
- -
KR
19.30 -4,113.87%
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.